Below are the most recent publications written about "Benzothiazoles" by people in Profiles.
-
Ran K, Yang J, Nair AV, Zhu B, Ran C. CRANAD-28: A Robust Fluorescent Compound for Visualization of Amyloid Beta Plaques. Molecules. 2020 Feb 16; 25(4).
-
Bruno PM, Lu M, Dennis KA, Inam H, Moore CJ, Sheehe J, Elledge SJ, Hemann MT, Pritchard JR. The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning. Proc Natl Acad Sci U S A. 2020 02 25; 117(8):4053-4060.
-
Afreen S, Bohler S, Müller A, Demmerath EM, Weiss JM, Jutzi JS, Schachtrup K, Kunze M, Erlacher M. BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells. Cell Death Dis. 2020 01 06; 11(1):8.
-
Zaldivar-Diez J, Li L, Garcia AM, Zhao WN, Medina-Menendez C, Haggarty SJ, Gil C, Morales AV, Martinez A. Benzothiazole-Based LRRK2 Inhibitors as Wnt Enhancers and Promoters of Oligodendrocytic Fate. J Med Chem. 2020 03 12; 63(5):2638-2655.
-
Garbern JC, Helman A, Sereda R, Sarikhani M, Ahmed A, Escalante GO, Ogurlu R, Kim SL, Zimmerman JF, Cho A, MacQueen L, Bezzerides VJ, Parker KK, Melton DA, Lee RT. Inhibition of mTOR Signaling Enhances Maturation of Cardiomyocytes Derived From Human-Induced Pluripotent Stem Cells via p53-Induced Quiescence. Circulation. 2020 01 28; 141(4):285-300.
-
Naskhi A, Jabbari S, Othman GQ, Aziz FM, Salihi A, Sharifi M, Sari S, Akhtari K, Abdulqadir SZ, Alasady AA, Abou-Zied OK, Hasan A, Falahati M. Vitamin K1 As A Potential Molecule For Reducing Single-Walled Carbon Nanotubes-Stimulated a-Synuclein Structural Changes And Cytotoxicity. Int J Nanomedicine. 2019; 14:8433-8444.
-
Zand Z, Khaki PA, Salihi A, Sharifi M, Qadir Nanakali NM, Alasady AA, Aziz FM, Shahpasand K, Hasan A, Falahati M. Cerium oxide NPs mitigate the amyloid formation of a-synuclein and associated cytotoxicity. Int J Nanomedicine. 2019; 14:6989-7000.
-
Weisberg E, Meng C, Case AE, Sattler M, Tiv HL, Gokhale PC, Buhrlage SJ, Liu X, Yang J, Wang J, Gray N, Stone RM, Adamia S, Dubreuil P, Letard S, Griffin JD. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. Br J Haematol. 2019 11; 187(4):488-501.
-
Haile PA, Casillas LN, Votta BJ, Wang GZ, Charnley AK, Dong X, Bury MJ, Romano JJ, Mehlmann JF, King BW, Erhard KF, Hanning CR, Lipshutz DB, Desai BM, Capriotti CA, Schaeffer MC, Berger SB, Mahajan MK, Reilly MA, Nagilla R, Rivera EJ, Sun HH, Kenna JK, Beal AM, Ouellette MT, Kelly M, Stemp G, Convery MA, Vossenkämper A, MacDonald TT, Gough PJ, Bertin J, Marquis RW. Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases. J Med Chem. 2019 07 25; 62(14):6482-6494.
-
Tahaei Gilan SS, Yahya Rayat D, Mustafa TA, Aziz FM, Shahpasand K, Akhtari K, Salihi A, Abou-Zied OK, Falahati M. a-synuclein interaction with zero-valent iron nanoparticles accelerates structural rearrangement into amyloid-susceptible structure with increased cytotoxic tendency. Int J Nanomedicine. 2019; 14:4637-4648.